Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Entrepreneur Helps Rural Women Shake off Poverty in Northwest China
Accelerating Development of Eco
Beautiful Family Moments — Through Children's Eyes
Iran helicopter crash that killed President Raisi could reverberate across the Middle East
Enhancing Business Development to Boost Rural Revitalization Following Poverty Alleviation
Uygur Woman Shows Charm of Xinjiang Through Fabulous Dance
Rural Woman Establishes Museum to Display Unique Charm of Miaos' Embroideries
California congressman urges closer consultation with tribes on offshore wind
China, Egypt discuss ways to boost tourism
'The Apprentice,' about a young Donald Trump, premieres in Cannes
Antiques Roadshow guest breaks down in tears over HUGE valuation of Edwardian cufflinks